EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

A randomised controlled trial of long NY-ESO-1 peptide-pulsed autologous dendritic cells with or without alpha-galactosylceramide in high-risk melanoma

Nathaniel Dasyam, Katrina J Sharples, Catherine Barrow, Ying Huang, Evelyn Bauer, Brigitta Mester, Catherine E Wood, Astrid Authier-Hall, Marina Dzhelali, Tess Ostapowicz, Rajiv Kumar, Jessica Lowe und 17 weitere

Cancer Immunology, Immunotherapy · 2023

DOI: 10.1007/s00262-023-03400-y ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Cancer Immunology, Immunotherapy, 2023. Verfasst von Nathaniel Dasyam und 28 weiteren Autor:innen. Beteiligte Einrichtung: Malaghan Institute of Medical Research, PO Box 7060, Wellington, 6242, New Zealand. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Research Council of New Zealand, Victoria University of Wellington.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

We have previously reported that polyfunctional T cell responses can be induced to the cancer testis antigen NY-ESO-1 in melanoma patients injected with mature autologous monocyte-derived dendritic cells (DCs) loaded with long NY-ESO-1-derived peptides together with α -galactosylceramide ( α -GalCer), an agonist for type 1 Natural Killer T (NKT) cells.

Objective

To assess whether inclusion of α -GalCer in autologous NY-ESO-1 long peptide-pulsed DC vaccines (DCV + α -GalCer) improves T cell responses when compared to peptide-pulsed DC vaccines without α -GalCer (DCV). Design, setting and participants Single-centre blinded randomised controlled trial in patients ≥ 18 years old with histologically confirmed, fully resected stage II–IV malignant cutaneous melanoma, conducted between July 2015 and June 2018 at the Wellington Blood and Cancer Centre of the Capital and Coast District Health Board.

Interventions

Stage I . Patients were randomised to two cycles of DCV or DCV + α -GalCer (intravenous dose of 10 × 10 6 cells, interval of 28 days). Stage II. Patients assigned to DCV + α -GalCer were randomised to two further cycles of DCV + α -GalCer or observation, while patients initially assigned to DCV crossed over to two cycles of DCV + α -GalCer. Outcome measures Primary: Area under the curve (AUC) of mean NY-ESO-1-specific T cell count detected by ex vivo IFN-γ ELISpot in pre- and post-treatment blood samples, compared between treatment arms at Stage I. Secondary: Proportion of responders in each arm at Stage I; NKT cell count in each arm at Stage I; serum cytokine levels at Stage I; adverse events Stage I; T cell count for DCV + α -GalCer versus observation at Stage II, T cell count before versus after cross-over.

Results

Thirty-eight patients gave written informed consent; 5 were excluded before randomisation due to progressive disease or incomplete leukapheresis, 17 were assigned to DCV, and 16 to DCV + α -GalCer. The vaccines were well tolerated and associated with increases in mean total T cell count, predominantly CD4 + T cells, but the difference between the treatment arms was not statistically significant (difference − 6.85, 95% confidence interval, − 21.65 to 7.92; P = 0.36). No significant improvements in T cell response were associated with DCV + α -GalCer with increased dosing, or in the cross-over. However, the NKT cell response to α -GalCer-loaded vaccines was limited compared to previous studies, with mean circulating NKT cell levels not significantly increased in the DCV + α -GalCer arm and no significant differences in cytokine response between the treatment arms.

Conclusions

A high population coverage of NY-ESO-1-specific T cell responses was achieved with a good safety profile, but we failed to demonstrate that loading with α -GalCer provided an additional advantage to the T cell response with this cellular vaccine design. Clinical trial registration: ACTRN12612001101875. Funded by the Health Research Council of New Zealand.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaSkin NeoplasmsMaleHumansAdolescentPeptidesAntibodiesCytokinesDendritic CellsAntigens, NeoplasmCutaneous Malignant MelanomaGalactosylceramides

Stichwörter der Autor:innen

Dendritic cellMelanomaNKT cellNY-ESO-1Vaccinationα-Galactosylceramide

Substanzen

PeptidesAntibodiesCytokinesAntigens, Neoplasmalpha-galactosylceramideGalactosylceramides

Autor:innen und Institutionen

  • Malaghan Institute of Medical Research, PO Box 7060, Wellington, 6242, New Zealand.
  • Dunedin School of Medicine, University of Otago, PO Box 56, Dunedin, 9054, New Zealand.
  • Cancer Trials New Zealand, University of Auckland, Private Bag 92019, Auckland, 1142, New Zealand.
  • Capital and Coast District Health Board, Private Bag 7902, Wellington, 6242, New Zealand.
  • School of Chemical Sciences, University of Auckland, PO Box 92019, Auckland, New Zealand.
  • Maurice Wilkins Centre for Molecular Biodiscovery, Private Bag 92019, Auckland, 1142, New Zealand.

Förderung

  • Health Research Council of New Zealand
  • Victoria University of Wellington

Zitieren

APA

Dasyam, N., Sharples, K. J., Barrow, C., Huang, Y., Bauer, E., Mester, B., Wood, C. E., Authier-Hall, A., Dzhelali, M., Ostapowicz, T., Kumar, R., Lowe, J., Maxwell, A., Burn, O. K., Williams, G. M., Carley, S. E., Caygill, G., Jones, J., Chan, S. T. S., …, & Hermans, I. F. (2023). A randomised controlled trial of long NY-ESO-1 peptide-pulsed autologous dendritic cells with or without alpha-galactosylceramide in high-risk melanoma. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-023-03400-y

Vancouver

Dasyam N, Sharples KJ, Barrow C, Huang Y, Bauer E, Mester B, et al. A randomised controlled trial of long NY-ESO-1 peptide-pulsed autologous dendritic cells with or without alpha-galactosylceramide in high-risk melanoma. Cancer Immunology, Immunotherapy. 2023. doi:10.1007/s00262-023-03400-y

BibTeX
@article{Dasyam2023,
  author = {Dasyam, Nathaniel and Sharples, Katrina J and Barrow, Catherine and Huang, Ying and Bauer, Evelyn and Mester, Brigitta and Wood, Catherine E and Authier-Hall, Astrid and Dzhelali, Marina and Ostapowicz, Tess and Kumar, Rajiv and Lowe, Jessica and Maxwell, Alice and Burn, Olivia K and Williams, Geoffrey M and Carley, Sarah E and Caygill, Graham and Jones, Jeremy and Chan, Susanna T S and Hinder, Victoria A and Macapagal, Jerome and McCusker, Monica and Weinkove, Robert and Brimble, Margaret A and Painter, Gavin F and Findlay, Michael P and Dunbar, P Rod and Gasser, Olivier and Hermans, Ian F},
  title = {A randomised controlled trial of long NY-ESO-1 peptide-pulsed autologous dendritic cells with or without alpha-galactosylceramide in high-risk melanoma},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2023},
  doi = {10.1007/s00262-023-03400-y}
}
Kostenlos starten →